2,942 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Kera Capital Partners Inc.

Kera Capital Partners Inc. purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,942 shares of the medical research company’s stock, valued at approximately $218,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Merit Financial Group LLC lifted its holdings in shares of Edwards Lifesciences by 30.9% in the 4th quarter. Merit Financial Group LLC now owns 5,581 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 1,316 shares during the last quarter. Avanza Fonder AB purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. RDA Financial Network boosted its holdings in shares of Edwards Lifesciences by 1.6% in the fourth quarter. RDA Financial Network now owns 33,770 shares of the medical research company’s stock valued at $2,500,000 after acquiring an additional 523 shares during the period. Empirical Asset Management LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $257,000. Finally, Central Valley Advisors LLC increased its holdings in shares of Edwards Lifesciences by 13.8% in the 4th quarter. Central Valley Advisors LLC now owns 17,639 shares of the medical research company’s stock valued at $1,306,000 after acquiring an additional 2,145 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.1 %

Edwards Lifesciences stock opened at $69.77 on Monday. The firm has a market capitalization of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock’s fifty day moving average is $72.06 and its two-hundred day moving average is $71.32.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm posted $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays increased their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Piper Sandler lowered their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group increased their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a report on Thursday. Finally, Stifel Nicolaus increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.